The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells

被引：7
|
作者：
Na, Yu Ran [1 ]
Kim, Jin Young [2 ]
Song, Chang Ho [1 ]
Kim, Mikyung [3 ]
Do, Yen Thi [1 ]
Vo, Tam Thuy Lu [3 ]
Choi, Eunsom [1 ]
Ha, Eunyoung [3 ]
Seo, Ji Hae [3 ]
Shin, So-Jin [1 ]
机构：
[1] Keimyung Univ, Sch Med, Dept Gynecol & Obstet, Daegu 42601, South Korea
[2] Keimyung Univ Sch Med, Dept Internal Med, Daegu 42601, South Korea
[3] Keimyung Univ Sch Med, Dept Biochem, Daegu 42601, South Korea
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2021年 / 22卷 / 19期
基金：
新加坡国家研究基金会;
关键词：
AZD4547; cancer stem cells; fibroblast growth factor; fibroblast growth factor receptor; ovarian cancer; FACTOR RECEPTOR FAMILY; ADVANCED SOLID TUMORS; LUNG-CANCER; SELECTIVE INHIBITOR; POTENT; AMPLIFICATION; CHEMOTHERAPY; MECHANISMS; DISCOVERY; SAFETY;
D O I：
10.3390/ijms221910817
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The dysregulation of fibroblast growth factor (FGF) signaling has been implicated in tumorigenesis, tumor progression, angiogenesis, and chemoresistance. The small-molecule AZD4547 is a potent inhibitor of FGF receptors. This study was performed to investigate the antitumor effects and determine the mechanistic details of AZD4547 in ovarian cancer cells. AZD4547 markedly inhibited the proliferation and increased the apoptosis of ovarian cancer cells. AZD4547 also suppressed the migration and invasion of ovarian cancer cells under nontoxic conditions. Furthermore, it attenuated the formation of spheroids and the self-renewal capacities of ovarian cancer stem cells and exerted an antiangiogenic effect. It also suppressed in vivo tumor growth in mice. Collectively, this study demonstrated the antitumor effect of AZD4547 in ovarian cancer cells and suggests that it is a promising agent for ovarian cancer therapy.
引用
收藏
页数：15
相关论文
共 50 条
  • [1] In vitro antitumor effect of AZD4547 in ovarian cancer cell lines.
    Seo, Ji Hae
    Lee, Seungmee
    Cho, Chi-Heum
    Shin, So-Jin
    CANCER RESEARCH, 2021, 81 (13)
  • [2] Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells
    Kwak, Yeonui
    Cho, Hanna
    Hur, Wooyoung
    Sim, Taebo
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (10) : 2292 - 2302
  • [3] FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
    Xie, Liang
    Su, Xinying
    Zhang, Lin
    Yin, Xiaolu
    Tang, Lili
    Zhang, Xiuhua
    Xu, Yanping
    Gao, Zeren
    Liu, Kunji
    Zhou, Minhua
    Gao, Beirong
    Shen, Danping
    Zhang, Lianhai
    Ji, Jiafu
    Gavine, Paul R.
    Zhang, Jingchuan
    Kilgour, Elaine
    Zhang, Xiaolin
    Ji, Qunsheng
    CLINICAL CANCER RESEARCH, 2013, 19 (09) : 2572 - 2583
  • [4] Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
    R. C. Coombes
    P. D. Badman
    J. P. Lozano-Kuehne
    X. Liu
    I. R. Macpherson
    I. Zubairi
    R. D. Baird
    N. Rosenfeld
    J. Garcia-Corbacho
    N. Cresti
    R. Plummer
    A. Armstrong
    R. Allerton
    D. Landers
    H. Nicholas
    L. McLellan
    A. Lim
    F. Mouliere
    O. E. Pardo
    V. Ferguson
    M. J. Seckl
    Nature Communications, 13
  • [5] Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
    Coombes, R. C.
    Badman, P. D.
    Lozano-Kuehne, J. P.
    Liu, X.
    Macpherson, I. R.
    Zubairi, I
    Baird, R. D.
    Rosenfeld, N.
    Garcia-Corbacho, J.
    Cresti, N.
    Plummer, R.
    Armstrong, A.
    Allerton, R.
    Landers, D.
    Nicholas, H.
    McLellan, L.
    Lim, A.
    Mouliere, F.
    Pardo, O. E.
    Seckl, M. J.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [6] Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547
    Kas, Sjors M.
    de Ruiter, Julian R.
    Schipper, Koen
    Schut, Eva
    Bombardelli, Lorenzo
    Wientjens, Ellen
    Drenth, Anne Paulien
    de Korte-Grimmerink, Renske
    Mahakena, Sunny
    Phillips, Christopher
    Smith, Paul D.
    Klarenbeek, Sjoerd
    van de Wetering, Koen
    Berns, Anton
    Wessels, Lodewyk F. A.
    Jonkers, Jos
    CANCER RESEARCH, 2018, 78 (19) : 5668 - 5679
  • [7] Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1
    Zuo-wei Wang
    Feng-ming Zou
    Ao-li Wang
    Jing Yang
    Rui Jin
    Bei-lei Wang
    Li-juan Shen
    Shuang Qi
    Juan Liu
    Jing Liu
    Wen-chao Wang
    Qing-song Liu
    Acta Pharmacologica Sinica, 2023, 44 : 801 - 810
  • [8] Evaluation of the pan-FGFR inhibitor AZD4547 with radiation in non-small cell lung cancer
    Miller, Margot
    Fisher, Michael
    Senthilkumar, Gopika
    Kaushik, Saakshi
    Able, Lindsey
    Brennan, Sean
    Iyer, Gopal
    Kimple, Randall
    Baschnagel, Andrew M.
    CANCER RESEARCH, 2019, 79 (13)
  • [9] Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1
    Wang, Zuo-wei
    Zou, Feng-ming
    Wang, Ao-li
    Yang, Jing
    Jin, Rui
    Wang, Bei-lei
    Shen, Li-juan
    Qi, Shuang
    Liu, Juan
    Liu, Jing
    Wang, Wen-chao
    Liu, Qing-song
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (04): : 801 - 810
  • [10] Mechanisms of Efficacy of the PAN-FGFR Inhibitor AZD4547 in Pediatric Solid Tumor Models
    Zage, P.
    Hakim, S.
    Subramonian, D.
    Lesperance, J.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S137 - S138
12345